N
Navneet Dhillon
Researcher at University of Texas MD Anderson Cancer Center
Publications - 5
Citations - 1264
Navneet Dhillon is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Curcumin & Peripheral blood mononuclear cell. The author has an hindex of 5, co-authored 5 publications receiving 1160 citations.
Papers
More filters
Journal ArticleDOI
Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer
Navneet Dhillon,Bharat B. Aggarwal,Robert A. Newman,Robert A. Wolff,Ajaikumar B. Kunnumakkara,James L. Abbruzzese,Chaan S. Ng,Vladimir Badmaev,Razelle Kurzrock +8 more
TL;DR: Oral curcumin is well tolerated and, despite its limited absorption, has biological activity in some patients with pancreatic cancer.
Journal ArticleDOI
Clinical findings of a palliative care consultation team at a comprehensive cancer center
TL;DR: The experience of a high-volume inpatient palliative care consultation team is described, providing insight into the demand and utility of this service for those considering the establishment of a PCCT.
Journal ArticleDOI
A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer.
Stacy L. Moulder,Navneet Dhillon,Chaan Ng,David S. Hong,Jennifer J. Wheler,Aung Naing,Susan Tse,Amy La Paglia,Robert T. Dorr,Evan M. Hersh,Michelle L. Boytim,Razelle Kurzrock +11 more
TL;DR: The maximum tolerated dose of imexon given with docetaxel in breast, prostate and non-small cell lung cancer (NSCLC) is established and demonstrated responses warrant further investigation in phase II trials.
Journal ArticleDOI
Cutaneous T Cell Lymphoma: Responses in Phase 1 Trial of Combination Therapy with Liposomal Doxorubicin, Bortezomib, and Gemcitabine.
TL;DR: The above combination is safe up to the doses tested so far- (dose level 5 = doxil 24mg/m2 on day1, gemcitabine 800 mg/ m2 on days 1 and 8 and bortezomib 1.0 mg/m3 on days1,4,8,11) and has activity in heavily pretreated, advanced cutaneous T-Cell lymphoma.
Journal ArticleDOI
Could Antitumor Activity of Curcumin in Patients Be due to Its Metabolites? A Response
TL;DR: It was found that vanillin and ferulic acid had no effect on suppression of tumor necrosis factor–induced NF-κB activation even at 200 μmol/L, whereas curcumin inhibited NF-σκB even at 10 μ mol/L (see [Fig. 1].